A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

665

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

May 31, 2029

Conditions

Small-cell Lung Cancer

Interventions

DRUG

ZL-1310 Dose Level 1

ZL-1310 Dose Level 1 as a single-agent

DRUG

ZL-1310 Dose Level 2

ZL-1310 Dose Level 2 as a single-agent

DRUG

Investigator's Choice of Therapy

Tarlatamab, Topotecan, Lurbinectedin, or Amrubicin

All Listed Sponsors

collaborator

Zai Lab (US) LLC

INDUSTRY

lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY